Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Berlin

Showing results (211-220 of 214) with videos related to

Pageof 22
Sort By:
You have reached the last page of results.This site can display upto 214 results.
ESMO Open|June 1, 2023
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022M Ducreux, G K Abou-Alfa, T Bekaii-Saab, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2015
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancerB H O'Neil, A J Scott, W W Ma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 21, 2015
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancerB H O'Neil, A J Scott, W W Ma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 6, 2016
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancerB H O'Neil, A J Scott, W W Ma, et al.
Pageof 22

Showing results (211-220 of 214) with videos related to

Sort By:
Pageof 22
You have reached the last page of results.This site can display upto 214 results.
ESMO Open|June 1, 2023
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022M Ducreux, G K Abou-Alfa, T Bekaii-Saab, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2015
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancerB H O'Neil, A J Scott, W W Ma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 21, 2015
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancerB H O'Neil, A J Scott, W W Ma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 6, 2016
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancerB H O'Neil, A J Scott, W W Ma, et al.
Pageof 22